Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.50
+1.6%		$25.96
$19.69
▼
$30.96
$5.00B0.811.80 million shs1.09 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.29
-0.6%		$253.63
$186.05
▼
$282.15
$15.89B0.39546,347 shs363,772 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.50
-1.7%		$78.85
$46.81
▼
$93.42
$16.21B0.962.32 million shs1.74 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.70
-1.4%		$60.67
$49.26
▼
$70.98
$13.10B0.242.33 million shs1.59 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.87%+2.33%+14.20%+37.63%+16.44%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.85%+3.48%-0.15%+3.14%+32.17%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.20%+2.13%+0.59%+19.99%+69.68%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.38%-1.24%+14.31%+25.12%+16.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$29.50
+1.6%		$25.96
$19.69
▼
$30.96
$5.00B0.811.80 million shs1.09 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$253.29
-0.6%		$253.63
$186.05
▼
$282.15
$15.89B0.39546,347 shs363,772 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$81.50
-1.7%		$78.85
$46.81
▼
$93.42
$16.21B0.962.32 million shs1.74 million shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$66.70
-1.4%		$60.67
$49.26
▼
$70.98
$13.10B0.242.33 million shs1.59 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
-3.87%+2.33%+14.20%+37.63%+16.44%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-1.85%+3.48%-0.15%+3.14%+32.17%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-1.20%+2.13%+0.59%+19.99%+69.68%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
-2.38%-1.24%+14.31%+25.12%+16.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.82
Moderate Buy$34.1915.91% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$300.3318.57% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7923.67% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.75
Moderate Buy$88.8333.17% Upside

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, ASND, and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$98.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/18/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$60.00 ➝ $59.00
8/17/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $49.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$82.00 ➝ $88.00
8/17/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$105.00 ➝ $111.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.07B4.74$0.90 per share32.74$7.58 per share3.89
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.40N/AN/A$26.78 per share9.46
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M31.73N/AN/A($12.81) per share-6.36
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B4.01$2.81 per share23.72$32.66 per share2.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.2213.2931.0522.8733.42%9.03%6.79%11/4/2026 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.6523.76N/A70.99%32.54%7.71%N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37180.2712.240.482.14%5.32%3.69%10/26/2026 (Estimated)

Latest ACAD, BBIO, ASND, and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
510172.31 million127.16 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable

Recent News About These Companies

BioMarin Pharmaceutical (BMRN) Agrees $490 Million Deal For Oral Rare Bone Disease Program
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-bmrn-agrees-490-200950154.html
40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC
August 21 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-40919-shares-in-biomarin-pharmaceutical-inc-bmrn-bought-by-paralel-advisors-llc-2026-08-21/
NFJ Investment Group LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN
August 21 at 6:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nfj-investment-group-llc-takes-position-in-biomarin-pharmaceutical-inc-bmrn-2026-08-21/
BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at BMO Capital Markets
August 21 at 2:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30973546
Therapeutics stocks Q2 results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
August 20 at 8:33 AM  |  msn.comhttps://www.msn.com/en-us/money/topstocks/therapeutics-stocks-q2-results-benchmarking-biomarin-pharmaceutical-nasdaqbmrn/ar-AA2aykf7
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to "Strong-Buy" at BMO Capital Markets
August 20 at 7:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/biomarin-pharmaceutical-nasdaqbmrn-raised-to-strong-buy-at-bmo-capital-markets-2026-08-20/
Edmond DE Rothschild Holding S.A. Purchases Shares of 687,030 BioMarin Pharmaceutical Inc. $BMRN
August 20 at 4:24 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-edmond-de-rothschild-holding-sa-purchases-shares-of-687030-biomarin-pharmaceutical-inc-bmrn-2026-08-20/
Eagle Health Investments LP Acquires Shares of 624,676 BioMarin Pharmaceutical Inc. $BMRN
August 20 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eagle-health-investments-lp-acquires-shares-of-624676-biomarin-pharmaceutical-inc-bmrn-2026-08-20/
HC Wainwright Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price
August 20 at 1:24 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971132
BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases
August 19 at 7:30 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/biomarin-pharmaceutical-bmrns-alesta-deal-adds-new-growth-potential-in-rare-diseases-1818053/
BioMarin Pharmaceutical to Acquire Alesta Therapeutics for up to $490 Million
August 19 at 12:57 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-acquire-alesta-therapeutics-130159491.html
BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
August 19 at 12:00 PM  |  cnbc.comhttps://www.cnbc.com/2026/08/19/biomarin-to-acquire-alesta-therapeutics-for-275-million.html
BioMarin Inks $490M Deal to Buy Rare Bone Disease Treatment
August 19 at 11:42 AM  |  zacks.comhttps://www.zacks.com/stock/news/2976951/biomarin-inks-490m-deal-to-buy-rare-bone-disease-treatment?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2976951
BMO Capital Markets Initiates Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN)
August 19 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/bmo-capital-markets-initiates-coverage-on-biomarin-pharmaceutical-nasdaqbmrn-2026-08-19/
GSA Capital Partners LLP Invests $944,000 in BioMarin Pharmaceutical Inc. $BMRN
August 19 at 3:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-gsa-capital-partners-llp-invests-944000-in-biomarin-pharmaceutical-inc-bmrn-2026-08-19/
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst Says
August 19 at 2:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30969358
Piper Sandler Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock
August 19 at 1:36 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30969168
BioMarin to Acquire Alesta in Cash Deal, Betting on First Oral HPP Therapy
August 19 at 1:07 AM  |  nai500.comN
BMRN stock rises on up to $490M Alesta deal, but analyst cuts price target to $59 — here’s why
August 19 at 1:07 AM  |  msn.comhttps://www.msn.com/en-us/money/general/bmrn-stock-rises-on-up-to-490m-alesta-deal-but-analyst-cuts-price-target-to-59-here-s-why/ar-AA2apenA
BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says
August 18 at 3:03 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biomarin-pharmaceutical-apos-alesta-deal-152509761.html
HC Wainwright Has Lowered Expectations for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price
August 18 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-lowered-expectations-for-biomarin-pharmaceutical-nasdaqbmrn-stock-price-2026-08-18/

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$29.50 +0.46 (+1.58%)
As of 04:00 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$253.29 -1.52 (-0.60%)
As of 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$81.50 -1.44 (-1.74%)
As of 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$66.70 -0.98 (-1.45%)
As of 04:00 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas